Charles River Laboratories International, Inc. (CRL) shares closed at USD 281.70 on September 17, 2026, posting a 3.0 percent gain as investors reacted positively to the launch of new rapid cell banking programs. These operational initiatives are designed to shorten release timelines for clients, addressing...
Arrowstreet Capital Limited Partnership reduced its stake in Charles River Laboratories International (NYSE:CRL) by 11.9% during the first quarter, selling 99,210 shares to hold a remaining position of 737,030 shares valued at approximately $127.1 million. While Arrowstreet decreased its holdings, several other institutional investors increased...
Institutional investors have made significant adjustments to their positions in Charles River Laboratories International (CRL) during the first quarter of 2026. Boston Trust Walden Corp reduced its stake by 6.4%, selling 19,452 shares and holding a remaining position valued at $49.2 million. Conversely, several other...
Charles River Laboratories stock traded near its yearly high on September 28, 2026, following a significant wave of analyst upgrades despite a weak reported revenue trend. Major financial institutions including Mizuho, JPMorgan, TD Cowen, and Robert W. Baird raised their price targets for the company,...
Charles River Laboratories International reported second-quarter results on August 5, 2026, showing a divergence between top-line revenue and earnings performance. The company generated USD 1 billion in revenue, representing a 2.7 percent year-over-year decline, while adjusted earnings per share (EPS) beat consensus estimates by USD...
Charles River Laboratories International, Inc. (CRL) shares are trading near record levels at $277.71 on the NYSE as of September 21, 2026, driven by a solid earnings outlook and strong investor confidence. The company has issued fiscal year 2026 guidance for earnings per share ranging...
Charles River Laboratories International, Inc. has launched new rapid cell banking programs that integrate Next-Generation Sequencing (NGS) to accelerate release timelines for biopharmaceutical and advanced therapy developers. This comprehensive end-to-end solution is designed to enhance product quality, safety, and regulatory readiness while significantly reducing overall...
Charles River Laboratories (CRL) reported a stronger-than-expected second quarter, delivering non-GAAP diluted EPS of $3.02 against the $2.73 consensus estimate. This result marked the fifth consecutive quarter where the company exceeded earnings expectations. Revenue reached $1.00 billion, surpassing the $977.20 million consensus by 2.75%, though...
Charles River Laboratories International reported second-quarter 2026 results that saw its stock fall 2.73% to close at $277.33 on the NYSE. While Q2 revenue declined 2.7% year-over-year to $1 billion, organic revenue growth was a modest 0.1%. Non-GAAP earnings per share dropped 3.2% to $3.02,...
Charles River Laboratories International, Inc. (CRL) shares have appreciated over 20% in the past year as management signaled a strategic inflection point at a September 2026 investor conference. The company projects manufacturing margins expanding to approximately 40% and expects annual free cash flow generation of...
Charles River Laboratories International, Inc. (CRL) stock closed at USD 283.98 on the New York Stock Exchange on September 8, 2026. The share price is currently trading slightly above the average analyst price target of USD 281, suggesting the market has priced in a portion...
Corient Private Wealth LLC significantly increased its position in Charles River Laboratories International (NYSE:CRL) by 68.5% during the fourth quarter, adding 7,166 shares to a total holding of 17,628 shares valued at $3.5 million. Several other institutional investors also entered new positions or increased stakes,...
Charles River Laboratories International (CRL) is currently under Wall Street scrutiny as analysts remain divided on its valuation and earnings outlook. The company recently reported first-quarter 2026 earnings on May 7, beating consensus estimates with EPS of $2.06 versus the expected $1.96. This beat supports...
Madison Small Cap Fund released its Q1 2026 investor letter, noting that while the fund slightly underperformed benchmarks, it maintained a preference for quality value stocks. The fund specifically highlighted Charles River Laboratories International (CRL) as a position that pulled back in the first quarter...
Charles River Laboratories International, Inc. (CRL) reported quarterly earnings of $2.06 per share for the quarter ended March 2026, surpassing the Zacks Consensus Estimate of $1.96 by 5.24%. This compares to adjusted earnings of $2.34 per share in the same quarter a year ago. Revenues...
Charles River Laboratories (CRL) reported a mixed second quarter characterized by a GAAP loss of $0.03 per share and a revenue decline of 2.7% year-over-year to $1.00 billion. The company posted the loss primarily due to a $63.7 million charge associated with divesting its CDMO...
Charles River Laboratories International Inc. (CRL) shares have surged significantly, closing at $281.67 on September 18, 2026, which aligns closely with a fair value estimate of approximately $282. The stock has delivered a robust 90-day gain of 52.25% and a one-year total shareholder return of...
Fifth Third Bancorp increased its stake in Charles River Laboratories International (CRL) by 51.2% during the first quarter, purchasing an additional 6,002 shares to hold a total of 17,733 shares valued at $3,059,000. This move joins a broader trend of institutional accumulation, with major entities...
Charles River Laboratories International (NYSE: CRL) reported first-quarter 2026 financial results that reflected a transition period following recent strategic divestitures and executive changes. Total revenue for the quarter was $995.8 million, representing a 1.2% increase year-over-year to Q1 2025. However, this growth masked underlying organic...
Charles River Laboratories International, Inc. (CRL) is set to release its first-quarter earnings report with Wall Street analysts forecasting quarterly EPS of $1.96 per share, which represents a 16.2% decline from the prior year. Revenue is expected to be approximately $971.06 million, marking a slight...
